{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:52:04Z","timestamp":1788623524246,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T00:00:00Z","timestamp":1475020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Research & Development, LLC, Raritan, N.J., USA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Risperidone, paliperidone, quetiapine, olanzapine, and aripiprazole are antipsychotic drugs approved for treating various psychiatric disorders, including schizophrenia. The objective of this randomized, parallel\u2010group, open\u2010label study was to compare finger\u2010stick\u2010based capillary with corresponding venous whole\u2010blood and plasma concentrations for these drugs after administration of a single dose to healthy volunteers. All whole\u2010blood and plasma drug concentrations were measured with validated liquid chromatography\u2013tandem mass spectrometry methods. Capillary and venous concentrations (both in plasma and whole blood) were in close agreement, although a time\u2010dependent difference was observed, most obviously for olanzapine and paliperidone, with slightly higher capillary versus venous drug concentrations during the first hours after administering a single dose. The observed difference between capillary and venous plasma drug concentrations is expected not to be relevant in clinical practice, considering the wide window of therapeutic concentrations and the wide range of drug concentrations in the patient population for a given dose. Based on these results, finger\u2010stick\u2010based capillary drug concentrations have been shown to approximate venous drug concentrations.<\/jats:p>","DOI":"10.1002\/cpdd.290","type":"journal-article","created":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T10:39:55Z","timestamp":1467369595000},"page":"528-537","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole"],"prefix":"10.1002","volume":"5","author":[{"given":"Bart","family":"Remmerie","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development Division of Janssen Pharmaceutica NV  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"De Meulder","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Division of Janssen Pharmaceutica NV  Beerse Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveta","family":"Weiner","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Savitz","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC  Raritan NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1286287"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-832687"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200404000-00014"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000249944.42859.bf"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2014.11.022"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.05.013"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198917040-00005"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280000179"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03668.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.100"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.16.27"},{"key":"e_1_2_11_13_1","unstructured":"2011 European Medicines Agency Guideline on bioanalytical method validation"},{"key":"e_1_2_11_14_1","unstructured":"2001 U.S. Department of Health and Human Services Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200010000-00015"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02408-12"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200111000-00011"},{"issue":"1","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4269\/ajtmh.1997.56.13","article-title":"Single\u2010dose, comparative study of venous, capillary and salivary artemisinin concentrations in healthy, male adults","volume":"56","author":"Sidhu JS","year":"1997","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"e_1_2_11_19_1","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun K","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-006-9040-2"},{"issue":"1","key":"e_1_2_11_21_1","first-page":"S19","article-title":"Population pharmacokinetics (PPK) of paliperidone ER in healthy and schizophrenia patients","volume":"81","author":"Cirincione BB","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140070-00003"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03223.x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007310385"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.544"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847070-00004"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.05.002"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00001"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.02.014"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009339190"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.290","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.290","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T22:23:28Z","timestamp":1696631008000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1002\/cpdd.290"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.290","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}